DexCare vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
DexCare raised $192M including a $75M Series C in June 2024 led by ICONIQ Growth; its health system platform has surpassed 3M patient visits scheduled; health system customers became investors.
About
DexCare is a Seattle-based digital health company that spun out of Providence in 2021. It provides a patient access and demand management platform that helps health systems balance patient demand against available care capacity — across virtual, in-person, and urgent care settings. Its AI-driven matching engine connects patients to the most appropriate care option (right care, right time, right location), improving both patient access and health system revenue per available slot.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.